Article
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Oncogene - 8 Jul 2010
Hecker R M, Amstutz R A, Wachtel M, Walter D, Niggli F K, Schäfer B W
Abstract excerpt
A number of drugs developed against cancer-specific molecular targets have been shown to offer survival benefits alone or in combination with standard treatments, especially for those cases in which tumor pathogenesis is dominated by a single molecular abnormality. One example for such a tumor type is alveolar rhabdomyosarcoma (aRMS), which is characterized by a specific translocation creating the oncogenic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.